文献速递临床试验与 GCP

早产儿初始复苏的靶向氧疗:TORPIDO 30/60 随机临床试验

Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

该随机临床试验在6国31家产科医院纳入胎龄23至28周的早产儿,比较初始吸入氧浓度0.6与0.3复苏对结局的影响。主要分析纳入728例(0.6组)和741例(0.3组),36周矫正胎龄时死亡或脑损伤发生率0.6组为46.9%(330/703),0.3组为47.8%(344/720),相对危险度0.98(95%CI 0.89-1.09)。结论认为初始吸入氧浓度0.6与0.3相比未影响死亡或脑损伤风险。

要点

  • 初始吸入氧浓度0.6组与0.3组的死亡或脑损伤发生率无显著差异,相对危险度为0.98(95%CI 0.89-1.09)。
  • 两组的吸入氧浓度升至1.0的比例相似:0.6组41%,0.3组38%。
  • 结果为进一步评估早产儿复苏使用较高初始吸入氧浓度的有效性和安全性奠定了基础。

核心结论

  • 初始复苏使用吸入氧浓度0.6与0.3相比,未影响36周矫正胎龄时的死亡或脑损伤风险。

研究设计与样本

  • 随机临床试验,在6个国家31家产科医院开展,纳入胎龄23至28周的早产儿,随机分为初始吸入氧浓度0.6组与0.3组。
  • 随机化时间为2018年9月至2024年9月,随访预计于2026年9月结束。
  • 主要分析纳入728例(0.6组)和741例(0.3组),排除172例,多数因胎龄超过28周分娩或产前转院;女性占54%。

主要发现

  • 主要结局信息在1423例新生儿(96.9%)中获得。
  • 36周矫正胎龄时死亡或脑损伤:0.6组330/703例(46.9%),0.3组344/720例(47.8%),相对危险度0.98(95%CI 0.89-1.09)。
  • 吸入氧浓度升至1.0的比例:0.6组41%,0.3组38%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The most effective initial fraction of inspired oxygen (Fio2) for resuscitating preterm newborns is unknown. OBJECTIVE: To compare outcomes of newborns born at 23 to 28 weeks' gestation resuscitated with initial Fio2 of 0.6 vs 0.3. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted in 31 maternity hospitals in 6 countries. Consent by waiver was obtained in Australia, certain institutions in India, and Malaysia; prospective informed consent was obtained in certain institutions in India and all institutions in Singapore, Spain, and the US. Infants due at 23 to 28 weeks' gestation were randomized shortly before birth. Those with congenital abnormalities affecting oxygenation, neurodevelopment, or survival were excluded. Randomization was conducted from September 2018 to September 2024, with follow-up expected to close in September 2026. INTERVENTION: Infants were randomized (1:1) to receive an initial Fio2 of 0.6 or 0.3; Fio2 was titrated to meet standard targets for oxygen saturation by pulse oximetry in the first 10 minutes or for clinical needs. Clinicians and those assessing outcomes were not blinded to group assignment. MAIN OUTCOMES AND MEASURES: The primary outcome was death and brain injury at 36 weeks' corrected gestational age; secondary outcomes were the individual components of the primary outcome. RESULTS: A total of 1641 newborns were randomized. The primary analysis included 728 newborns randomized to receive an Fio2 of 0.6 and 741 to an Fio2 of 0.3 after excluding 172 newborns, mostly for birth after 28 weeks' gestation and transfer to another hospital before birth (54% female). Rates of escalation to Fio2 of 1.0 were similar between the groups (Fio2 of 0.6: 41%; Fio2 of 0.3: 38%). Primary outcome information was ascertained in 1423 newborns (96.9%). Death or brain injury at 36 weeks' corrected gestational age occurred in 330 of 703 newborns (46.9%) assigned to the Fio2 of 0.6 group vs 344 of 720 (47.8%) assigned to the Fio2 of 0.3 group (relative risk, 0.98 [95% CI, 0.89-1.09]). CONCLUSIONS AND RELEVANCE: Initiating resuscitation of preterm infants with Fio2 of 0.6 vs 0.3 did not affect the risk of death or brain injury by 36 weeks' corrected gestational age. These results lay a foundation for future trials evaluating the effectiveness and safety of using higher initial Fio2 levels for preterm infant resuscitation. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618000879268.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Oei JL, Kirby A, Travadi J, et al. Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial. JAMA. 2026. PMID: 41369162. doi:10.1001/jama.2025.23327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。